Clinical trials on Solid tumor

Solid Tumor Overview

Solid tumors are masses of tissue that form when cells grow and multiply uncontrollably. Unlike blood cancers, which spread through the body’s liquid systems, solid tumors remain in one area and can be benign (non-cancerous) or malignant (cancerous). These tumors can originate in any body organ, such as the brain, breast, or liver, making their impact and treatment methods highly varied. The complexity of solid tumors is further compounded by their ability to create their own blood supply, facilitating their growth and potentially aiding in the spread of cancerous cells to other parts of the body—a process known as metastasis.

The diagnosis and treatment of solid tumors involve a multidisciplinary approach, including surgery, radiation therapy, chemotherapy, and targeted therapy. Imaging techniques such as MRI, CT scans, and PET scans play a crucial role in diagnosing and monitoring the progress of these tumors. Moreover, advancements in genomic profiling have paved the way for personalized medicine, allowing for treatments to be tailored to the genetic makeup of an individual’s tumor. This approach has shown promise in improving outcomes and reducing the side effects of treatment. Despite these advancements, the battle against solid tumors remains challenging, with ongoing research focused on understanding tumor biology and developing new therapeutic strategies.

  • CT-EU-00119004

    Testing Vemurafenib and Cobimetinib for BRAF Positive Cancers

    This clinical trial is for patients with cancers that have a specific change in their cancer cells known as BRAF V600 mutation. It uses two drugs, vemurafenib and cobimetinib, to see if they can effectively treat various types of cancers such as solid tumors, haematological malignancies, melanoma, thyroid cancer, ovarian neoplasms, colorectal neoplasms, laryngeal neoplasms, non-small-cell lung carcinoma, glioma, multiple myeloma, and Erdheim-Chester disease. The purpose of this study is to determine if these drugs can help treat cancers with the BRAF V600 mutation.

    In the study, participants will receive both drugs until their disease progresses, they experience unacceptable side effects, or they decide to withdraw. Blood samples will be collected at different times during the treatment for research purposes. Participants will be monitored every three months for two years after completing the treatment.

    • Vemurafenib
    • Cobimetinib
  • Study ANV419 as monotherapy or in combination with pembrolizumab and ipilimumab in patients with metastatic melanoma

    The aim of this study is to test a new drug called ANV419. It will be given alone or in combination with other approved cancer medicines such as pembrolizumab or ipilimumab. The main goal is to see how well ANV419 works and whether it is safe for people with advanced cutaneous melanoma, which is a type of skin cancer that has spread or cannot be surgically removed.

    The trial is currently open to adult patients who have already been treated with drugs that target PD-1 or PD-L1 proteins, but whose cancer has continued to progress. The study will have different parts. First, doctors will find the right dose of ANV419 to use alone or in combination with other treatments. They will then check how many patients respond to treatment, which means their tumors shrink or stop spreading.

    • ANV419
    • Ipilimumab
    • Pembrolizumab
  • Testing of a new antibody (RO7247669) in patients with metastatic cancers

    This clinical trial is testing a new drug called RO7247669. This is a special type of antibody that targets two proteins in cancer cells, PD-1 and LAG-3. The goal is to see if this new drug can help fight advanced or metastatic solid tumors such as melanoma, lung cancer and esophageal cancer.

    In the first part of the study, researchers will administer different doses of RO7247669 to patients every 2 or 3 weeks through a drip. They will watch closely for any side effects and toxicities that may occur. Once they determine the highest safe dose, they will move on to the next section.

    In the second part, they will give the highest safe dose to more patients with a specific type of cancer. The most important thing they will look for will be how well the drug works against the tumors, such as whether they shrink for a while or stop growing. They will also monitor you for any side effects for up to 2 years.

    The aim of this study is to find the best and safest dose of this new dual-acting antibody drug and whether it will be able to effectively fight advanced solid tumors.

    • RO7247669
  • CT-EU-00091258

    Study of Idasanutlin in combination with chemotherapy or other drugs in acute leukemia patients

    This study involves testing a new medication, Idasanutlin, for patients with recurrent or challenging-to-treat leukemias or solid tumors. In certain cases, the new medication will be administered in combination with other anti-cancer drugs, either traditional chemotherapy medications or Venetoclax. The primary objective is to assess the medication for potential side effects and its effectiveness in treating the disease. Initially, efforts will focus on determining a safe and well-tolerated dose for the new medication. Subsequently, the study will further investigate the safety and initial effectiveness of combining this drug with others in three groups: neuroblastoma, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL).

    • Idasanutlin
    • Cytarabine
    • Fludarabine
    • topotecan
    • Cyclophosphamide
    • Venetoclax
  • Extended safety study for participants using spartalizumab alone or combined

    This study relates to a type of medication called spartalizumab. The goal is to find out if this medicine, when given alone or with other treatments, is safe and doesn’t cause any unwanted side effects. The study is open to people who have already been involved in past studies for spartalizumab. The reason for this is to keep giving these people access to the treatment while also continuously assessing its safety.

    • spartalizumab/PDR001
  • Safety study of new treatment in locally advanced or metastatic solid tumors

    This study is focused on researching a new treatment called RO7502175 for various serious types of cancer, including lung cancer, stomach cancer, cervical cancer, and more. The primary objectives of the study are to assess the safety of RO7502175, study its movement within the body (pharmacokinetics), and evaluate its potential to slow down or halt these types of cancer. Additionally, the researchers aim to investigate the effectiveness of this new treatment when used alone and in combination with another drug called atezolizumab. The study is divided into two parts. In the first part, the researchers will initiate with a smaller dose of the drug and gradually increase it to determine the optimal dosage. Once the appropriate dose is established, the second part of the study will involve treating a larger group of participants with this determined dosage.

    • RO7502175- new potential medication for solid tumors
    • Atezolizumab
  • Study on genetic vaccine for unstable solid tumors

    The clinical trial is studying a new vaccine, Nous-209, in combination with pembrolizumab, a cancer drug, to treat certain solid tumors that have specific genetic changes. It is for adults with advanced colorectal, gastric, or gastroesophageal junction tumors. The study has two phases. The first phase tests different doses for safety and to find the best dose. The second phase tests how effective this combination is in treating the cancer. Patients receive the vaccine by injection and are followed for their response to the treatment. The goal is to see if this new treatment can help people with these types of tumors.

    • Nous-209
    • Pembrolizumab
  • Continuing dabrafenib and trametinib treatment for cancer patients

    This clinical trial offers ongoing access to dabrafenib and trametinib for patients already receiving these drugs in previous studies. It targets various cancers, including melanoma and non-small cell lung cancer. The study aims to assess the long-term safety and tolerability of these drugs, either used separately or in combination. It is important for patients who have shown benefits from these treatments in past trials. The trial will closely monitor adverse events and the clinical benefits for up to ten years, ensuring patient safety and treatment effectiveness.

    • dabrafenib
    • trametinib
  • Studying immunoradiotherapy for metastatic tumors

    This clinical trial is all about improving the health of people who have metastatic solid tumors – that is, tumors that have started to spread to other parts of the body. The trial consists of two phases. In the initial phase, the goal is to determine the optimal safe dosage for use. Subsequently, in phase two, a comparison will be made between two treatment approaches to identify the more effective option. These include (1) radiotherapy combined with a medication known as GEN1042, and (2) radiotherapy with both GEN1042 and another drug called pembrolizumab. Vigilant monitoring will be maintained to assess the body’s response, with a primary focus on tumor responsiveness and potential side effects. The trial aims to enhance comprehension of tumor growth or reduction and overall participant health.

    • GEN1042
    • Pembrolizumab
  • Examining a new treatment for solid tumours

    This clinical trial explores AZD8205, a potential new treatment for individuals with advanced or metastatic solid tumors. It’s currently in Phase 1 and 2, focusing on evaluating the safety, effectiveness, and overall impact of AZD8205. The goal is to see how safe it is, how bodies react to it, how long the drug takes to start and stop working, how it affects cancer cells, and how it’s processed in our bodies. Doctors will look at side effects, especially any that happen soon after the first dose. The trial aims to understand how well AZD8205 works in treating these challenging cancers and its effects on patients’ health.

    • AZD8205- new potential medication for solid tumors
  • Study on a new medicine for hematological malignancies and solid tumors

    This study is the first of its kind where OT-A201, a unique double-targeting antibody, is used to treat patients with certain types of blood cancers and solid tumors. The study is divided into two parts. The first part is about figuring out the safest and most effective dose of OT-A201 to give to patients, either on its own, or in combination with other treatments (Lenalidomide, Pomalidomide, Bevacizumab or Paclitaxel). The second part of the study is to see how well this treatment works on stopping or slowing down the growth of cancer cells. Throughout the study, researchers will closely watch for any negative side effects, including those which may cause patients to stop treatment, and check-ups will include lab tests, vital signs check, ECGs, and physical examinations.

    • OT-A201-a new medicine for hematological malignancies and solid tumors
    • Pomalidomide
    • Bevacizumab
    • Lenalidomide
    • Paclitaxel
  • Study on the interactions between cancer drug Brigimadlin and other drugs

    In the context of a clinical trial conducted on individuals with advanced cancer, the investigation focuses on how a drug known as Brigimadlin (BI 907828), a potential cancer treatment, may interact with other medications. These include rifampicin (used for bacterial infections) and itraconazole (used against fungal infections). The study will consist of two groups – each participant will receive Brigimadlin every three weeks. The first group will also take rifampicin during their second treatment cycle, while the second group will take itraconazole starting a week into their second cycle and continuing for the next 20 days. The study will continue for as long as it benefits the participants, and they can tolerate the treatment. Blood samples will be collected periodically to monitor Brigimadlin levels, and close observation will be maintained for any changes in health and potential side effects.

    • Brigimadlin/BI 907828
    • Rifampicin
    • Itraconazole
  • Study on new medicine and immune drugs for hard-to-treat tumors

    The safety and efficacy of a new drug, Zanzalintinib (XL092) is currently evaluated in investigation in a trial designed for individuals with inoperable solid tumors or those that have metastasized. The drug may be administered as a standalone treatment or in combination with other medications designed to stimulate the immune system’s response to combat cancer. The initial phase focuses on determining the appropriate dosage for Zanzalintinib. Subsequently, the trial aims to assess the effectiveness of Zanzalintinib and companion drugs in reducing tumor size and enhancing survival rates. Throughout the study, potential adverse reactions to the drug will also be monitored. During the second stage, the evaluation of Zanzalintinib will be expanded to analyze outcomes in patients with specific cancer types. The objective is to investigate whether the drug leads to a slower progression of cancer and a reduction in tumor size for individuals with these particular types of cancer.

    • Relatlimab
    • Zanzalintinib/XL092
    • Nivolumab
    • Ipilimumab
  • Testing a new potential drug for advanced tumors

    In this study, a new cancer drug named INT-1B3 is being tested, with a focus on people with serious types of cancer that are not responding to other treatments. INT-1B3 operates through multiple mechanisms to inhibit the growth and spread of cancer cells. The study is in two parts. In the first part, researchers aim to determine the safe dosage of the medication by establishing the maximum amount that can be administered without causing adverse side effects. In the second part, will further explore safety, pharmacokinetics (fate of the drug in the body), and antitumor activity. Throughout the study, researchers will meticulously monitor any undesired effects and their severity.

    • INT-1B3- new potential medication for advanced tumors
  • Research on using new therapy for treating advanced tumors

    This research is about a new medicine named INCB123667. It may help people who have serious cancers that have spread to other parts of the body. The trial has two parts. Part 1 will find out the best dose to use and if it causes any side effects. Part 2 will see if the medicine helps shrink the cancer cells. Doctors will check for side effects the first time the medicine is given. If side effects are severe, the medicine dose will be reduced. The timing of when the drug is given may also need to be changed. Doctors will measure the highest amount of the drug in the blood and how fast it reaches this level. They’ll also see how long it stays in the system and how quickly the body gets rid of it. Successful treatment would mean the cancer stops growing or shrinks.

    • INCB0123667- new potential medication for advanced malignancies
  • Testing the safety of a new drug on advanced or metastatic solid tumors

    This study is about checking how safe a medicine called TNG462 is for people with advanced or metastatic solid tumors that have a specific genetic change called MTAP deletion. The study will involve a total of 159 patients. At first, they will focus on finding the right amount of medicine that can be given to the patients. Then, they will see how well this treatment works on different types of MTAP-deleted tumors. The drug is taken by mouth and the treatment will continue for those who don’t have any serious side effects until there’s a sign that their disease is getting worse. They’ll also study how the body absorbs, uses, and gets rid of this drug.

    • TNG462-new potential medication for solid tumors with MTAP deletion
  • Testing new medication for advanced or spread-out solid tumors

    This research study is about checking if a new medicine, known as INCA33890, is safe for people who have advanced or metastatic solid tumors. This trial is important because it needs to be checked if this medicine can work safely without causing too much trouble or side effects for the person taking it. An important part of this trial is also to figure out how much of this medicine can be given safely to a person, so it helps to treat their cancer but doesn’t make them sick from the treatment itself.

    • INCA33890- new potential medication for solid tumors
  • Study of a new drug in the treatment of solid tumors

    This study involves a drug called PYX-201, which is being studied in participants who have advanced solid tumors. Generally, the study may include people whose tumor has returned or has not responded to other treatments. The primary goal is to determine the best dose of PYX-201 for these participants. Particular attention will be paid to identifying any potential side effects, and the study aims to investigate how the medicine works in the body. Specifically, the study will look at whether PYX-201 can effectively control or limit tumor growth, as well as assess participants’ responses to the drug.

    • PYX-201- new potential medication for solid tumors
  • Study on customized therapy for advanced solid tumors

    The research study, now in its second phase, aims to examine if particular treatments, or treatment combinations, are safe and useful in treating certain hard-to-remove or spreading tumors. These treatments are personalized, chosen depending on certain genetic changes detected in a person’s tumor. It will take about 4 weeks to see if the treatment is successful. As part of the study, patients will have to answer some questions about their physical, emotional, mental, and social health, which will help paint a clear picture of their overall quality of life. Lastly, any negative impacts causes by the treatment are taken note of and classified according to their severity.

    • Divarasib/GDC-6036
    • Ipatasertib
    • Idasanutlin
    • Belvarafenib
    • Camonsertib
    • Pralsetinib
    • Entrectinib
    • Alectinib
    • Atezolizumab
    • Inavolisib
    • Trastuzumab Emtansine
  • Studying repotrectinib effect on advanced solid tumors

    In this trial, the researchers are working on a new medicine called Repotrectinib, targeting people with specific types of advanced solid tumors. This medicine might be most helpful if cancer has certain genetic changes, specifically those called ALK, ROS1, or NTRK1-3. It is an early stage of testing Repotrectinib in two parts or phases. During Phase 1,the researchers are trying to find out what the right dose is. It is important to look at the highest dose that can be given without causing too many side effects, and also the dose makes a difference in how the cancer behaves. This phase will also look at how the medication is processed by the body and how it behaves in the system. The second phase will check how well the medicine works in different groups of people, with some details about their cancer and the treatments they have had in the past. It is important to check if the medicine can shrink the tumors and stop them from growing. The researchers will also measure how long these effects last, how quickly these effects occur.

    • Repotrectinib